This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
BayerPRO IRE Above Brand Header

Oncology Products

About NUBEQA® (darolutamide)
Access key information about NUBEQA® (darolutamide).
PP-NUB-IE-0264-1, December 2025
About Xofigo®▼ (radium-223 dichloride)
Access key information about Xofigo®.
PP-XOF-IE-0127-1, January 2026

Oncology Latest Resources

Xofigo®▼ (radium-223 dichloride) | Resources
Explore resources to learn more about Xofigo®.
PP-XOF-IE-0132-1, February 2026
NUBEQA® (darolutamide) | Metastasis Free Survival
Explore NUBEQA and its impact on metastasis-free survival in nmCRPC.
PP-NUB-IE-0265-1, December 2025
NUBEQA® (darolutamide) | Overall Survival​
Explore NUBEQA and its impact on overall survival.
PP-NUB-IE-0266-1, December 2025
NUBEQA® (darolutamide) | Morbidity
Explore NUBEQA® and its secondary endpoints.
PP-NUB-IE-0267-1, December 2025